Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.43 |
| ▸ | FABP7 | O15540 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16381002 | 0.73 | FABP5 (0.55) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL31684010 | 0.73 | FABP5 (0.55) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL22532087 | 0.73 | KMT2A (0.49) | KMT2AFABP5FABP7EPHX2TSHR | |
| SCHEMBL28516206 | 0.73 | TDP1 (0.53) | KMT2ATSHRCASP3 | |
| SCHEMBL44676 | 0.72 | KMT2A (0.58) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL15981181 | 0.72 | KMT2A (0.58) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL27837757 | 0.72 | KMT2A (0.51) | KMT2AFABP5FABP7EPHX2TSHR | |
| SCHEMBL12016740 | 0.71 | KMT2A (0.56) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL44677 | 0.71 | FABP5 (0.59) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL2782675 | 0.71 | KMT2A (0.56) | KMT2AFABP5FABP7EPHX2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109219436-B | Modified wound dressing | 康沃特克科技公司 | 2025-05-23 | — | — | CN | disclosed |
| US-12257323-B2 | Modified wound dressings | CONVATEC TECHNOLOGIES INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20240123091-A1 | MODIFIED WOUND DRESSINGS | CONVATEC TECHNOLOGIES, INC. | 2024-04-18 | — | — | US | disclosed |
| US-11865192-B2 | Modified wound dressings | CONVATEC TECHNOLOGIES, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| EP-3436012-B1 | MODIFIED WOUND DRESSINGS | CONVATEC TECHNOLOGIES INC (US) | 2023-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240123091-A1 | MODIFIED WOUND DRESSINGS | MMP8, CD68, ELANE | KMT2A 3296/4885FABP5 887/4885FABP7 1601/4885 |
| US-11865192-B2 | Modified wound dressings | MMP8, CD68, ELANE | KMT2A 3296/4885FABP5 887/4885FABP7 1601/4885 |
| US-12257323-B2 | Modified wound dressings | MMP8, CD68, ELANE | KMT2A 3296/4885FABP5 887/4885FABP7 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.